Yu A - Search Results

1

Structural Modification and Pharmacological Evaluation of Substituted Quinoline-5,8-diones as Potent NSD2 Inhibitors.

Tang H, Yu A, Xing L, Chen X, Ding H, Yang H, Song Z, Shi Q, Geng M, Huang X, Zhang A. Tang H, et al. Among authors: yu a. J Med Chem. 2023 Jan 26;66(2):1634-1651. doi: 10.1021/acs.jmedchem.2c01920. Epub 2023 Jan 15. J Med Chem. 2023. PMID: 36642961

2

Structure-Based Discovery of a Series of NSD2-PWWP1 Inhibitors.

Li N, Yang H, Liu K, Zhou L, Huang Y, Cao D, Li Y, Sun Y, Yu A, Du Z, Yu F, Zhang Y, Wang B, Geng M, Li J, Xiong B, Xu S, Huang X, Liu T. Li N, et al. Among authors: yu a, yu f. J Med Chem. 2022 Jul 14;65(13):9459-9477. doi: 10.1021/acs.jmedchem.2c00709. Epub 2022 Jun 15. J Med Chem. 2022. PMID: 35704853

3

Discovery of a potent and selective proteolysis targeting chimera (PROTAC) degrader of NSD3 histone methyltransferase.

Sun Y, Zhang Y, Chen X, Yu A, Du W, Huang Y, Wu F, Yu L, Li J, Wen C, Yang H, Shi Q, Geng M, Huang X, Xu S. Sun Y, et al. Among authors: yu l, yu a. Eur J Med Chem. 2022 Sep 5;239:114528. doi: 10.1016/j.ejmech.2022.114528. Epub 2022 Jun 13. Eur J Med Chem. 2022. PMID: 35717870

4

Piribedil disrupts the MLL1-WDR5 interaction and sensitizes MLL-rearranged acute myeloid leukemia (AML) to doxorubicin-induced apoptosis.

Zhang X, Zheng X, Yang H, Yan J, Fu X, Wei R, Xu X, Zhang Z, Yu A, Zhou K, Ding J, Geng M, Huang X. Zhang X, et al. Among authors: yu a. Cancer Lett. 2018 Sep 1;431:150-160. doi: 10.1016/j.canlet.2018.05.034. Epub 2018 May 30. Cancer Lett. 2018. PMID: 29857126

5

[A review of immune-related adverse events associated with immunotherapy].

Fang Y, Yu Y, Wu DW, Fang H, Huang HY, Wang SH, Yu AQ, Sun C, Bai Y, Wang H, Li N. Fang Y, et al. Among authors: yu aq, yu y. Zhonghua Zhong Liu Za Zhi. 2020 Jan 23;42(1):17-21. doi: 10.3760/cma.j.issn.0253-3766.2020.01.002. Zhonghua Zhong Liu Za Zhi. 2020. PMID: 32023764 Chinese.

6

Inflammatory Bowel Disease and Its Association With Perinuclear Antineutrophil Cytoplasmic Antibodies: A Systematic Review.

Kaur H, Kasapoglu M, Yadavalli R, Nawaz S, Althwanay A, AlEdani EM, Yu AK. Kaur H, et al. Among authors: yu ak. Cureus. 2024 Apr 8;16(4):e57872. doi: 10.7759/cureus.57872. eCollection 2024 Apr. Cureus. 2024. PMID: 38725759 Free PMC article. Review.

7

A rare missense PAX6 mutation causes atypical aniridia in a three-generation Chinese family.

Lin ZB, Feng CY, Li J, Pan AP, Sun HS, Yu AY, Chen SH. Lin ZB, et al. Among authors: yu ay. Int J Ophthalmol. 2024 Mar 18;17(3):466-472. doi: 10.18240/ijo.2024.03.07. eCollection 2024. Int J Ophthalmol. 2024. PMID: 38721508 Free PMC article.

8

The Growing Class of Novel RNAi Therapeutics.

Traber GM, Yu AM. Traber GM, et al. Among authors: yu am. Mol Pharmacol. 2024 May 6:MOLPHARM-MR-2024-000895. doi: 10.1124/molpharm.124.000895. Online ahead of print. Mol Pharmacol. 2024. PMID: 38719476 Free article.

9

Repeatability and agreement of 4 biometers measuring corneal astigmatism in eyes with irregular corneal astigmatism component.

Wang L, Shao X, Fu JL, Hu JJ, Zhou KJ, Li R, Yu AY. Wang L, et al. Among authors: yu ay. Am J Ophthalmol. 2024 May 6:S0002-9394(24)00200-9. doi: 10.1016/j.ajo.2024.05.002. Online ahead of print. Am J Ophthalmol. 2024. PMID: 38719132

10

TGFβ Signaling Dysregulation May Contribute to COL4A1-Related Glaucomatous Optic Nerve Damage.

Mao M, Kuo YM, Yu AK, Labelle-Dumais C, Ou Y, Gould DB. Mao M, et al. Among authors: yu ak. Invest Ophthalmol Vis Sci. 2024 May 1;65(5):15. doi: 10.1167/iovs.65.5.15. Invest Ophthalmol Vis Sci. 2024. PMID: 38717426

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

4,505 results

Search Page